期刊文献+

甲状腺乳头状癌行预防性中央区淋巴结清扫术研究进展 被引量:3

Research development of prophylactic central lymph node dissection for papillary thyroid cancer
原文传递
导出
摘要 甲状腺乳头状癌(PTC)是最常见的甲状腺恶性肿瘤,预后良好.但颈部淋巴结转移却很常见,其中最常见的转移区域是颈部中央区(即Ⅵ区).目前对于临床可疑或确定有颈淋巴结转移者,需行治疗性中央区颈淋巴结清扫术,国内外观点基本一致,然而对于cN0 PTC患者是否应该常规行预防性中央区颈淋巴结清扫术仍存较大争议.本文就PTC行预防性中央区颈淋巴结清扫术研究进展做一综述. Papillary thyroid cancer (PTC) is the most common malignant neoplasm originating from the thyroid gland and has an excellent prognosis.But cervical lymph node metastases are common and the most common sites of metastases are the central lymph nodes of the neck (level Ⅵ).While therapeutic central lymph node dissection for involved lymph nodes is needed in our nation and others,the controversial topic is whether routine prophylactic central lymph node dissection in patients without evidence of lymph node metastasis should be performed in patients with PTC.The author reviewed the research development of prophylactic central lymph node dissection for papillary thyroid cancer in the article.
出处 《国际外科学杂志》 2015年第2期126-129,共4页 International Journal of Surgery
关键词 甲状腺乳头状癌 中央区淋巴结 颈淋巴结清扫术 综述 预后 Papillary thyroid cancer Central lymph node Neck dissection Review Prognosis
  • 相关文献

参考文献1

共引文献7

同被引文献57

  • 1中华医学会内分泌学分会,中华医学会外科学分会内分泌学组,中国抗癌协会头颈肿瘤专业委员会,中华医学会核医学分会.甲状腺结节和分化型甲状腺癌诊治指南[J].中华核医学与分子影像学杂志,2013,33(2):96-115. 被引量:3
  • 2Jung CK, Little MP, Lubin JH, et al. The Increase in thyroidcancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations[ J. J Clin Endocrinol Metab, 2014, 99 (2) : E276- E285. 被引量:1
  • 3Ellis RJ, Wang Y, Stevenson HS, et al. Genome-wide methy|ation patterns in papillary thyroid cancer are distinct based on histological subtype and tumor genotype [ J ]. J Clin Endocrinol Metab, 2014, 99 (2) : E329-E337. 被引量:1
  • 4Hall RD, Kudchadkar RR. BRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies [ J ]. Cancer Control, 2014, 21 (3) : 221-230. 被引量:1
  • 5Khan MS, Pandith AA, Azad N, et al. Impact of molecular alterations of BRAF in the pathogenesis of thyroid cancer [ J ]. Mutagenesis, 2014, 29 (2) : 131-137. 被引量:1
  • 6Duhz LA, Dhar S, Ogilvie JB, et al. Clinical and therapeutic implications of Sprouty2 feedback dysregulation in BRAF V600E- mutation-positivepapillary thyroid cancer[ J]. Surgery, 2013, 154 (6/, 1239-1245. 被引量:1
  • 7Yim JH, Kim WG, Jeon M J, et al. Association between expression of X-linked inhibitor of apoptosis protein and the clinical outcome in a BRAFV6OOE-prevalent papillary thyroid cancer population [ J ]. Thyroid, 2014,24 ( 4 ) : 689 -694. 被引量:1
  • 8Huang Y, Liao D, Pan L, et al. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV6OOE mutation [ J ]. Eur J Endocrinol, 2013, 168 ( 5 ) : 675-681. 被引量:1
  • 9Liu X, Qu S, Liu R, et al. TERT promoter mutations and their association with BRAFV600E mutation and aggressive clinicopathological characteristics of thyroid cancer [ J ]. J Clin Endocrinol Metab, 2014, 99(6) :E1130-E1136. 被引量:1
  • 10Xing M, Liu R, Liu X , et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroidcaneer with highest recurrence[ J]. J Clin Oncol, 2014, 32 (25) :2718-2726. 被引量:1

引证文献3

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部